New Release! Free Pulmonary Arterial Hypertension On-Demand CE

Just Released! Free, On-Demand CE on PAH

Navigating the Complex Landscape of Pulmonary Arterial Hypertension: A Roadmap for Pharmacists

The last 30 years have seen significant advances in the diagnosis, treatment, and management of pulmonary arterial hypertension (PAH). Improvements in understanding the pathways underlying endothelial dysfunction and vascular arteriole remodeling involved in the pathogenesis of PAH, targeted therapies, and enhanced diagnostic and monitoring tools are reflected in new evidence-based guidelines.

This educational activity will present the latest guidelines and recommended treatment options for PAH, including drug selection, combination therapies, and when and how to adjust and escalate treatment. This activity will also discuss drug therapy mechanisms of action, potential interactions, adverse effects, and considerations to support access and adherence. 

Access Now



We invite you to share this free educational activity with your colleagues. 

Featuring...

Jared Frost

PharmD, BCCP
Activity Chair

 

Clinical Pharmacy Specialist– Cardiology 

Cardiology Pharmacy Residency Director
Advocate Health – Aurora St. Luke's Medical Center
Milwaukee, Wisconsin 

Zachary Klick 

PharmD, BCCP, BCPS, BCACP, CPP 

 

Cardiology Pharmacist

Cardiology Pharmacy Residency Program Director

Atrium Health Wake Forest Baptist

Winston Salem, North Carolina 

Target Audience​

This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, ambulatory clinics, and community settings who care for or are interested in the care of patients with pulmonary arterial hypertension.

Learning Objectives

  • Summarize the pathophysiology and disease progression of PAH, with a focus on pathways that are therapeutic targets for treatment.
  • Apply guideline-directed risk stratification for PAH to select treatment options and distinguish risk status as an indicator of disease progression.
    Analyze the rationale and evidence for combining therapies to simultaneously target multiple pathways.
  • Identify how to initiate, adjust and escalate combination therapy to reach treatment goals using the latest evidence and guidelines.
  • Apply the mechanisms of action, clinical efficacy, safety, dosing, administration, and real-world experience of therapies to treat PAH.

Agenda

Welcome and Introductions
Jared Frost
 

Pathophysiology and diagnosis of pulmonary arterial hypertension (PAH)

Zachary Klick
 

Guidelines and Evidence-based Treatment of PAH

Jared Frost
 

Therapy Considerations for PAH 

All Faculty
 

Faculty Discussion, Questions and Answers

All Faculty

Accredited for CPE

ACPE #: 0204-0000-25-409-H01-P

CE Credit: 1.5 contact hours (0.15 CEUs)

Activity Type: Application-based

Activity Fee: No charge 

Available: February 19, 2026 - February 19, 2027

 

To receive CE credit, complete the steps below within 60 days of completing the activity.

  1. View entire presentation and answer all polling questions.
  2. Click "Complete Activity" on the last slide to complete the evaluation.
  3. Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.

After the 60-day deadline, ASHP will no longer be able to report credit(s).

 

To view all of the activities offered online, click here.

購物車 會員登入